Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Non-Current Deffered Revenue: 2012-2019

Historic Non-Current Deffered Revenue for Ptc Therapeutics (PTCT) over the last 5 years, with Dec 2019 value amounting to $3.4 million.

  • Ptc Therapeutics' Non-Current Deffered Revenue fell 80.03% to $1.8 million in Q1 2020 from the same period last year, while for Mar 2020 it was $1.8 million, marking a year-over-year decrease of 80.03%. This contributed to the annual value of $3.4 million for FY2019, which is 64.87% down from last year.
  • Ptc Therapeutics' Non-Current Deffered Revenue amounted to $3.4 million in FY2019, which was down 64.87% from $9.7 million recorded in FY2018.
  • In the past 5 years, Ptc Therapeutics' Non-Current Deffered Revenue registered a high of $9.7 million during FY2018, and its lowest value of $1.6 million during FY2016.
  • Its 3-year average for Non-Current Deffered Revenue is $7.0 million, with a median of $8.0 million in 2017.
  • Per our database at Business Quant, Ptc Therapeutics' Non-Current Deffered Revenue surged by 401.20% in 2017 and then slumped by 64.87% in 2019.
  • Yearly analysis of 4 years shows Ptc Therapeutics' Non-Current Deffered Revenue stood at $1.6 million in 2016, then soared by 401.20% to $8.0 million in 2017, then rose by 22.23% to $9.7 million in 2018, then crashed by 64.87% to $3.4 million in 2019.